FDA (CDER)
GUIDANCE FINAL
Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers
Published: 4/15/2026Detected: 4/17/2026
Summary preview
Clarifies FDA’s expanded access pathway for using investigational drugs when patients lack satisfactory alternatives, including how requests are submitted, reviewed, and authorized.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
pediatrics
oncology
infectious_disease
#expanded access
#compassionate use
#investigational drugs
#FDA review
#safety reporting
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026